Wolverine is a two-component research blend containing BPC-157 and TB-500 in a single 3mL pen totalling 20mg. It is supplied for laboratory research use only.
Wolverine pairs the two peptides most frequently studied together in preclinical tissue research, at 10mg each. Supplying them pre-combined removes one reconstitution and transfer step for laboratories running them in combination.
Both components are studied in connection with cell migration and tissue models. Both have evidence bases that are preclinical in nature — rodent models and cell culture — and neither has established efficacy in humans for any indication.
We state that plainly because the gap between the preclinical literature and what is sometimes claimed about these two peptides is unusually wide.
BPC-157 is a pentadecapeptide corresponding to a partial sequence of body protection compound, identified in gastric juice. It is notably stable in aqueous solution, which is one reason it appears frequently in in-vitro method development. Preclinical work has examined angiogenic signalling pathways and cell migration.
TB-500 corresponds to the actin-binding region of thymosin β4. Thymosin β4 is one of the most abundant proteins in many mammalian cell types and is involved in actin sequestration. Research with the fragment focuses on actin polymerisation and cell motility assays.
The two act on different parts of cell migration and tissue models, which is the stated rationale for combination work in the preclinical literature. Whether the combination produces any effect beyond the components individually has not been established.
Batch documentation for Wolverine is available on request where we hold it. We do not publish a public batch database, and no purity, identity, sterility or manufacturing claim is stated anywhere on this site unless documentation for that exact batch supports it. To ask what is held for a particular lot, contact us.
These are starting points for your own reading, not endorsements of any conclusion.
A single 3mL pen containing 20mg in total: BPC-157 10mg and TB-500 10mg.
No. The current and correct specification is 20mg total — BPC-157 10mg plus TB-500 10mg. Any earlier reference to a 40mg presentation with 20mg of each component is obsolete and has been removed.
No. Both have preclinical evidence bases built on cell culture and rodent models. Neither has established efficacy in humans for any indication.
GLOW and KLOW both contain the same BPC-157 10mg and TB-500 10mg, with GHK-Cu added in GLOW and GHK-Cu plus KPV added in KLOW. Wolverine is the two-peptide pairing on its own.
This product is supplied strictly for in-vitro laboratory research. It is not a medicine, is not licensed by the MHRA, and is not for human or veterinary consumption or administration. We do not supply dosing, reconstitution or administration guidance, and nothing on this page is a therapeutic claim.